Get the Stockscreener App
1.28
4.07%
0.05
After Hours:
1.22
-0.06
-4.69%
Cumberland Pharmaceuticals Inc stock is traded at $1.28, with a volume of 28,262.
It is up +4.07% in the last 24 hours and down -5.19% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$1.23
Open:
$1.25
24h Volume:
28,262
Relative Volume:
3.53
Market Cap:
$18.04M
Revenue:
$39.55M
Net Income/Loss:
$-6.28M
P/E Ratio:
-9.8462
EPS:
-0.13
Net Cash Flow:
$5.64M
1W Performance:
+3.23%
1M Performance:
-5.19%
6M Performance:
-23.81%
1Y Performance:
-32.28%
1-Day Range:
$1.20
$1.5099
1-Week Range:
$1.20
$1.5099
52-Week Range:
$1.20
$2.3587
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Intravenous Ibuprofen Industry Size, Share, Price, Trends, Forecast (2024-2034) - உங்கள் குரல்
Intravenous Ibuprofen Industry Size, Share, Price, Trends, Forecast (2024-2034) - Third Eye News
Intravenous Ibuprofen Industry Size, Share, Price, Trends, Forecast (2024-2034) - Talented India
Scleroderma Diagnostics and Therapeutics Market Size, Share, Growth and Industry Trends - Third Eye News
Mira Pharmaceuticals (NASDAQ:MIRA) Stock Quotes, Forecast and News Summary - Benzinga
Cumberland Pharma stock hits 52-week low at $1.2 amid challenges - Investing.com India
Cumberland Pharma stock hits 52-week low at $1.2 amid challenges - Investing.com Australia
Dilated Cardiomyopathy Market to Show Remarkable Growth Trends - openPR
Dilated Cardiomyopathy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Bristol Myers Squibb, Berlin Cures, Cumberland Pharmaceuticals, Vericel Corporation, Corimmun - Barchart
Asthma Market is Predicted to Exhibit Remarkable Growth During - openPR
Battling Superbugs: Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report 2024 - WhaTech
Global mTOR Inhibitors Market Innovations Investigated by Size and Share 2024 - WhaTech
Hepatorenal Syndrome Treatment Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech
Anthracyclines Market Strategic Insights Growth Path to 2031 - meramandsaur.in
Gardner Syndrome Treatment Market Projected Growth Outlined by Share, Trends, Size, Major Players And Forec... - WhaTech
Methotrexate Injection Market: A Comprehensive Overview - openPR
Cumberland Pharma stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Cumberland Pharma stock hits 52-week low at $1.25 By Investing.com - Investing.com Australia
Cumberland Pharma stock hits 52-week low at $1.25 - Investing.com
Cumberland Pharma stock hits 52-week low at $1.25 By Investing.com - Investing.com UK
Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com - Defense World
State of New Jersey Common Pension Fund D Lowers Stock Holdings in Sea Limited (NYSE:SE) - Defense World
LPL Financial LLC Has $46.81 Million Stake in iShares Fallen Angels USD Bond ETF (NASDAQ:FALN) - Defense World
North America Anthracyclines Market By Application - Third Eye News
Autoimmune Treatment Market Competitor Analysis, Growth, Insights, Trends 2024-2033 - WhaTech
Duchenne Muscular Dystrophy Drugs Market Size, Regional Demand, Trends and Forecast to 2024-2032 - Talented India
Bloom Syndrome Treatment Market to Exhibit a Remarkable CAGR - openPR
Drugs for Xerostomia Industry Growth Factors, Applications, and Forecast by (2024-2034) – news - Isothermal Nucleic Acid ...
Cumberland Pharma stock hits 52-week low at $1.32 - Investing.com
Peptide Antibiotics Market to Exhibit a Remarkable CAGR of 5.50% - openPR
Duchenne Muscular Dystrophy Drugs Market Size, Regional Demand, Trends and Forecast to 2024-2032 - அக்னி செய்திகள்
Cumberland Pharmaceuticals (NASDAQ:CPIX) Earns Hold Rating from Analysts at StockNews.com - Defense World
North America Vasoconstrictor Drugs Market By Application : Size, Trends, Growth and Forecast 2031 - அக்னி செய்திகள்
Methotrexate Drugs Market Projected To Witness Substantial - openPR
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com - Defense World
Cumberland Pharma stock hits 52-week low at $1.34 - Investing.com India
Cumberland Pharma stock hits 52-week low at $1.34 - Investing.com
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Update - Defense World
Antimicrobial Resistance Market Outlook: Valued at $4.95 Billion in 2023 with a Projected 7.6% CAGR Through 2032 - Taiwan News
Zevra Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Pericarditis Industry is Expected to Reach Huge Growth by 2031 - openPR
Earnings call: Cumberland Pharmaceuticals sees robust Q2 growth - Investing.com
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2024 Earnings Call Transcript - Insider Monkey
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript - Seeking Alpha
Cumberland: Q2 Earnings Snapshot - CTPost
Cumberland: Q2 Earnings Snapshot - San Antonio Express-News
Cumberland: Q2 Earnings Snapshot - Houston Chronicle
Cumberland: Q2 Earnings Snapshot - San Francisco Chronicle
Cumberland: Q2 Earnings Snapshot - Danbury News Times
Cumberland: Q2 Earnings Snapshot - Crossville Chronicle
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 - PR Newswire
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):